Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
Standard
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein. / Raadsen, Matthijs P; Dahlke, Christine; Fathi, Anahita; Lamers, Mart M; van den Doel, Petra; Zaeck, Luca M; van Royen, Martin E; de Bruin, Erwin; Sikkema, Reina; Koopmans, Marion; van Gorp, Eric Cm; Sutter, Gerd; de Vries, Rory D; Addo, Marylyn M; Haagmans, Bart L.
In: J INFECT DIS, Vol. 228, No. 5, 31.08.2023, p. 586-590.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
AU - Raadsen, Matthijs P
AU - Dahlke, Christine
AU - Fathi, Anahita
AU - Lamers, Mart M
AU - van den Doel, Petra
AU - Zaeck, Luca M
AU - van Royen, Martin E
AU - de Bruin, Erwin
AU - Sikkema, Reina
AU - Koopmans, Marion
AU - van Gorp, Eric Cm
AU - Sutter, Gerd
AU - de Vries, Rory D
AU - Addo, Marylyn M
AU - Haagmans, Bart L
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/8/31
Y1 - 2023/8/31
N2 - Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
AB - Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
KW - Antibodies, Neutralizing
KW - Antibodies, Viral
KW - Broadly Neutralizing Antibodies
KW - Coronavirus Infections/prevention & control
KW - Humans
KW - Middle East Respiratory Syndrome Coronavirus
KW - Monkeypox virus
KW - Spike Glycoprotein, Coronavirus
KW - Vaccinia virus/genetics
KW - Viral Vaccines
U2 - 10.1093/infdis/jiad052
DO - 10.1093/infdis/jiad052
M3 - SCORING: Journal article
C2 - 36857443
VL - 228
SP - 586
EP - 590
JO - J INFECT DIS
JF - J INFECT DIS
SN - 0022-1899
IS - 5
ER -